Inactive Instrument

News BioLineRx Ltd. TEL AVIV STOCK EXCHANGE

Equities

BLRX

IL0011015182

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	May. 06	PU
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	Apr. 17	PU
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	Apr. 17	CI
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	Apr. 10	PR
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	Apr. 10	CI
BioLineRx Announces $6 Million Registered Direct Offering	Apr. 02	AQ
BioLineRx Shares Fall After $6 Million Registered Direct Offering	Apr. 01	MT
BioLineRx : Form 20-F/A (Amendment No. 1	Mar. 28	PU
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	Mar. 27	AQ
BioLineRx : Annual Report on Form 20-F FOR 2023	Mar. 26	PU
Transcript : BioLineRx Ltd., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
BioLineRx : Report of Periodic or Interim Report	Mar. 26	PU
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	Mar. 26	PU
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	Mar. 20	PR
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	Mar. 04	PR
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production	Mar. 04	CI
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer	Feb. 28	CI
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?	Feb. 16	CI
BioLineRx : FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933	Dec. 31	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioLineRx Ltd. TEL AVIV STOCK EXCHANGE

Equities

BLRX

IL0011015182

Summary

Filters